Resistance or pitfall in heparin monitoring: An ongoing issue in COVID-19 anticoagulation.

Alsagaff, Mochamad Yusuf; Mulia, Eka Prasetya Budi

Alsagaff, Mochamad Yusuf; Mulia, Eka Prasetya Budi.

Alsagaff MY; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia.
Mulia EPB; Universitas Airlangga Hospital, Surabaya, Indonesia.

Int J Lab Hematol ; 44(4): e135-e137, 2022 08.

Article in English | MEDLINE | ID: covidwho-1573698

Subject(s)

COVID-19; Heparin; Anticoagulants/pharmacology; Anticoagulants/therapeutic use; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors/pharmacology; Heparin/therapeutic use; Humans; Partial Thromboplastin Time

Keywords

COVID-19; activated partial thromboplastin time; anti-Xa; heparin; intensive care; resistance

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Heparin / COVID-19 Limits: Humans Language: English Journal: Int J Lab Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: Ijlh.13778

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google